Nplus1 Brewin Reiterates “Sell” Rating for BTG (BTG)
BTG (LON:BTG)‘s stock had its “sell” rating restated by stock analysts at Nplus1 Brewin in a report issued on Wednesday, ARN reports. They currently have a GBX 490 ($8.07) target price on the stock. Nplus1 Brewin’s price objective suggests a potential downside of 19.08% from the company’s current price.
BTG (LON:BTG) opened at 595.00 on Wednesday. BTG has a 52 week low of GBX 313.70 and a 52 week high of GBX 624.00. The stock has a 50-day moving average of GBX 583.3 and a 200-day moving average of GBX 453.6.
Several other analysts have also recently commented on the stock. Analysts at FinnCap reiterated a “sell” rating on shares of BTG in a research note to investors on Wednesday. They now have a GBX 345 ($5.68) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of BTG in a research note to investors on Tuesday. They now have a GBX 630 ($10.38) price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of BTG from GBX 610 ($10.05) to GBX 635 ($10.46) in a research note to investors on Friday, January 24th. They now have a “buy” rating on the stock. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 524.78 ($8.65).
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.